Home > Thoracic Oncology
  • FILTER YOUR SEARCH
    Content Type:
  • Thoracic Oncology

    Thoracic Oncology

    Although the incidence and mortality from lung cancer is decreasing in some Western countries due to decades of public education and tobacco control policies, it remains a major cause of mortality worldwide. The treatment landscape for non-small-cell lung cancer (NSCLC) has been transformed in the past decade, thanks to the development of immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and therapies targeting specific genetic alterations.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities

    Thoracic Oncology Content

    Journal articles and more to your inbox


    Get the latest clinical insights from touchRESPIRATORY

    Sign me up!
    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowlinkmenumore_dots padlock person play-colourAsset 1podcastprinter search share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrow